A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

Part of paid clinical trials in Brisbane, California.

Sponsor
Vera Therapeutics, Inc.
Study ID
NCT06674577
Phase
PHASE2
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Atacicept 150 mg — DRUG
    The atacicept drug product is available as a ready to use injection solution in the following prefilled syringe (PFS) that is composed of: \*BD Hypak™ SCF™ Barrel Glass barrel 1ml long with staked needle 27G ½" 5B with Rigid Needle Shield BD260 \*BD SCF™ Stopper 1ml long W4023 Flurotec

Study Details

The purpose of this study is to collect long-term safety and tolerability data for atacicept in patients with IgAN that completed Vera trial investigating atacicept in IgAN population.

Key Dates

Start date
Dec 1, 2024
Status verified
Dec 2024
Primary completion
May 31, 2028
Completion
May 31, 2028

Study Design

Enrollment
476 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Atacicept 150mg once weekly subcutaneous (SC) injection
    Other Names: VT-001

Primary Outcome Measure

Incidence of adverse events observed during the dosing period [ Time Frame: Baseline until end of study up to week156 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Vera TherapeuticsBrisbaneCalifornia94005-

Find similar trials in Brisbane, CA

By research site
Vera Therapeutics· Brisbane, CA

Related Studies